Skip to main content
. 2018 Feb 14;4:24. doi: 10.1038/s41420-018-0032-y

Fig. 6. Compound #2714 showed a strong anticancer effect and pharmacodynamics profile in vivo.

Fig. 6

a Lewis lung carcinoma (LL/2) cells were injected subcutaneously into female C57BL/6 mice and inoculated for 10 days. These mice, with LL/2-bearing tumors, were then intraperitoneally (i.p.) administered with 100, 50, or 25 mg/kg #2714; vehicle was used as a control. Tumor volumes were measured every other day for 14 days starting from the initiation of treatment. b Growth inhibition rates were measured by weighing the tumors of experimental animals killed at the end of the experiment after #2714 was administered to LL/2-bearing mice xenograft models. c The average body weight changes of each group were measured every other day. d A significant increase in survival in #2714-treated mice was observed. e An immunohistochemical analysis was conducted to detect the effects of #2714 on tumor angiogenesis inhibition and apoptosis induction by detecting CD31 and CD105 after animals were administered #2714 for 14 days. A TUNEL assay was used to detect the LL/2-bearing tumor mice xenograft sections. The representative fields of tumor sections from the TUNEL assay were observed under an inverted fluorescence microscope with a camera (log-rank, mean ± SEM, n = 10, 200×; *p < 0.05, **p < 0.01)